Navigation Links
MabVax Therapeutics Initiates Phase II Clinical Trial of Vaccine to Prevent Recurrent Sarcoma
Date:7/22/2010

SAN DIEGO, July 22 /PRNewswire/ -- MabVax Therapeutics Inc., a privately held clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer, announces that the first patients have been enrolled in a Phase II clinical trial aimed at assessing the efficacy and safety of its vaccine to prevent or delay the recurrence of sarcoma. The clinical trial will enroll 126 metastatic sarcoma patients, 16 years or older in a randomized, multicenter, double-blind Phase II study of a trivalent vaccine specifically developed to target and kill residual circulating cancer cells and micrometastases thought to cause recurrent cancer.  

In the United States (US), there are approximately 13,200 sarcoma cases diagnosed each year, representing less than 1% of all new cancers.  Prognosis remains poor, with more than 5,200 patients in the US dying of disease each year.  As in other malignancies, disease recurrence and metastasis are common in sarcoma.  Despite undergoing potentially curative surgical resection or combination therapy, the majority of these patients with recurrent sarcoma die as a result of further recurrences.  The addition of chemotherapy to surgical resection has not shown to improve outcome in adult patients with sarcoma. Thus, in the majority of cases, the current standard of care following treatment of metastatic disease and the achievement of disease-free status is expectant management.

The vaccine is a trivalent ganglioside vaccine administered with an immunological adjuvant in a series of 10 subcutaneous injections given over an 84-week period.  The vaccine is intended to instruct the patient's immune system to make antibodies against the three ganglioside ant
'/>"/>

SOURCE MabVax Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... 2015 Bionomics Limited (ASX:BNO, ADR:BMICY), a biopharmaceutical ... therapeutics for the treatment of cancer and diseases of ... data from three of its most advanced oncology programs ... 106 th Annual Meeting being held from April ... USA. The presentation on the BNC105 ...
(Date:4/16/2015)... April 16, 2015 Vanda Pharmaceuticals Inc. (Vanda) ... the development and commercialization of products for the treatment ... release results for the first quarter of 2015 on ... The Company will host a conference call ... during which Vanda management will discuss the first quarter ...
(Date:4/16/2015)... 16, 2015 A drug commonly taken to prevent ... with multiple sclerosis (MS), according to a study released today ... 67th Annual Meeting in Washington, DC , ... of people with MS experience at some point in their ... nerve carrying vision from the eye to the brain gets ...
Breaking Medicine Technology:Bionomics Showcases Oncology Drug Development Programs at 2015 AACR Annual Meeting 2Bionomics Showcases Oncology Drug Development Programs at 2015 AACR Annual Meeting 3Bionomics Showcases Oncology Drug Development Programs at 2015 AACR Annual Meeting 4Bionomics Showcases Oncology Drug Development Programs at 2015 AACR Annual Meeting 5Vanda Pharmaceuticals to Announce First Quarter 2015 Financial Results on May 6, 2015 2Epilepsy Drug May Preserve Eyesight for People with MS 2
... Calif., Nov. 5 Bionovo, Inc. (Nasdaq: BNVI ... the unmet needs in women,s health and oncology, today ... three months ended September 30, 2009. , Subsequent to ... successfully completed a public offering and issued approximately 31 ...
... , SAN DIEGO, Nov. 5, 2009 Amylin Pharmaceuticals, Inc. ... Annual Credit Suisse Healthcare Conference in Phoenix, Arizona on Wednesday, ... ET. Mark Foletta, senior vice president of finance and ... corporate overview. , The audio portion of the presentation will ...
Cached Medicine Technology:Bionovo Announces Third Quarter 2009 Highlights and Financial Results 2Bionovo Announces Third Quarter 2009 Highlights and Financial Results 3Bionovo Announces Third Quarter 2009 Highlights and Financial Results 4Bionovo Announces Third Quarter 2009 Highlights and Financial Results 5Bionovo Announces Third Quarter 2009 Highlights and Financial Results 6Bionovo Announces Third Quarter 2009 Highlights and Financial Results 7Bionovo Announces Third Quarter 2009 Highlights and Financial Results 8Bionovo Announces Third Quarter 2009 Highlights and Financial Results 9
(Date:4/18/2015)... 18, 2015 Carinsurancequotesinfo.com has released a ... cover physical injuries caused by a car accident. ... coverage for a vehicle. A policy can pay for ... accident. Drivers should always carry appropriate coverage when they ... can be bought with several important riders that offer ...
(Date:4/18/2015)... "I wanted to live a ... healthful juice that contained essential vitamins, minerals and ... increases my energy, improves skin elasticity and gives ... Tapp's Juice to contain fruits, vegetables and other ... and mental fatigue. It features a great taste. ...
(Date:4/18/2015)... (PRWEB) April 18, 2015 Lower-auto-insurance.com has ... accurate auto insurance quotes . , ... policies by comparing quotes. A professional insurance brokerage website ... insurance quotes, in a simple, convenient way. The whole ... to anyone. , Comparing online car insurance quotes ...
(Date:4/18/2015)... (PRWEB) April 18, 2015 More than ... sale now at TheCelebrityDresses.com, the #1 online store carrying ... ongoing many girls have got their perfect dresses for ... the celebrity fashion prom dresses at TheCelebrityDresses.com would be ... designed more than 2000 prom dresses inspired by the ...
(Date:4/18/2015)... (PRWEB) April 18, 2015 PHOENIX, ARIZONA ... County, along with 11 other secure destruction professionals across ... Destruction Specialists (CSDS). He will now display “CSDS” as ... were offered before the National Association of Information Destruction ... and another Grapevine, Texas. Of the 20 people who ...
Breaking Medicine News(10 mins):Health News:Auto Insurance Plans Can Cover Physical Injuries Caused By An Accident! 2Health News:Auto Insurance Quotes Can Provide Accurate Results! 2Health News:Prom Dresses 2015 on Sale at TheCelebrityDresses.com 2
... Calif., May 7 The CPF today announced that the ... would authorize $16 million in new federal funding for pulmonary ... 27 Members of the U.S. House of Representatives. The ... and awareness of pulmonary fibrosis, a terminal lung disease with ...
... HMSY ) today announced that it will present ... Conference, which will be held Tuesday, May 12 ... City. The Company will present on Tuesday, May 12th at ... be accessed through our website at http://www.hms.com/investor_relations/investors_presentations.asp ...
... Conseco, Inc. (NYSE: CNO ) today responded ... subscribers who hold Conseco, Inc. stock vote for eight ... dissident nominee for the ninth director up for election."RMG ... to elect a dissident at Conseco,s upcoming annual meeting ...
... Facial Surgery in a Live Case Study for TWTRCON ... TWTRCON SF 09, the first conference focused on ... Operation Smile would be launching a groundbreaking new fundraising ... creating a live case study in which TWTRCON attendees ...
... May 7 /PRNewswire/ - Axela Inc., is pleased to ... dotLab(R) System that provides technical controls to support compliance ... will be of particular interest to those working in ... secure database, audit trails, electronic signature controls and user ...
... the U.S. once again a resounding successNEW YORK, May ... friends and supporters, joined the more than 10,000 people ... April 25th to celebrate the 15th Parkinson,s Unity Walk ... Parkinson,s disease research.This year marked an incredible year for ...
Cached Medicine News:Health News:Co-Sponsorship of Pulmonary Fibrosis Research Enhancement Act 2009 Increases to 27 Members 2Health News:Co-Sponsorship of Pulmonary Fibrosis Research Enhancement Act 2009 Increases to 27 Members 3Health News:Co-Sponsorship of Pulmonary Fibrosis Research Enhancement Act 2009 Increases to 27 Members 4Health News:Operation Smile To Launch Groundbreaking 140 Smiles Fundraising Campaign at TWTRCON SF 09 2Health News:Operation Smile To Launch Groundbreaking 140 Smiles Fundraising Campaign at TWTRCON SF 09 3Health News:Axela introduces software to support 21 CFR Part 11 Compliance for Regulated Environments 2Health News:15th Parkinson's Unity Walk A Step in the Right Direction for Parkinson's Community 2Health News:15th Parkinson's Unity Walk A Step in the Right Direction for Parkinson's Community 3
P-Series Cystourethroscope Short Bridge, examining...
Short single-horn bridge for insertion of instruments...
Albarran double-horn bridge for use with sheaths from 20-25 Fr and designed for accurate articulation of flexible devices....
Designed for accurate articulation of flexible devices....
Medicine Products: